Business Wire

Sartorius Looks Ahead to Sustained, Highly Profitable Growth – Sales Revenue to Rise to around 4 Billion Euros by 2025

Jaa

Sartorius, a leading international technology partner of the biopharmaceutical industry and research laboratories, intends to continue on its profitable growth track over the long term. According to its new medium-term targets that will be presented today at the company’s annual press conference and its Capital Markets Day, the Group expects to achieve sales of around 4 billion euros in 2025. Management’s plan is to achieve around two-thirds of this growth organically while around one-third is to be generated by acquisitions.

Accordingly, the Group’s underlying EBITDA margin is forecasted to rise by 2025 to around 28%. The Bioprocess Solutions Division is expected to grow to around 2.8 billion in sales revenue with an underlying EBITDA margin of around 30% by 2025; for the Lab Products & Services Division, sales revenue of around 1.2 billion euros and an EBITDA margin of about 25% are projected for the full year of 2025. (All figures of the mid-term guidance given in constant currencies.)

“Our targets remain ambitious because we have positioned ourselves well for the future and address a market with sustainable, fundamental growth drivers,” said Group CEO Dr. Joachim Kreuzburg. “We assume that demand for biopharmaceutical drugs will continuously increase due to a growing and aging population, improved access to medicines in emerging countries, a rapidly expanding market for biosimilars and also due to completely new, emerging treatment options such as cell-based therapies. In this respect, the Asian market will play an increasingly important role, primarily China. We positioned ourselves with our two divisions as a global strategic partner of the biopharma sector so that we should sustainably benefit from these trends. With our broad and innovative product portfolio and the early expansion of our production capacities, we are well prepared for further growth.”

Business development of the Sartorius Group in 2017

The groundwork for reaching the Group’s targets has been laid: In 2017, Sartorius achieved an increase in sales revenue by 9.3% in constant currencies to 1,404.6 million euros, up from 1,300.3 million euros a year ago (reported: +8.0%), and increased its underlying earnings to 353.2 million euros. Organic growth and acquisitions contributed almost equally to growth.

"In 2017, Sartorius continued on its profitable growth track, executed two strategically important acquisitions, moved forward on its extensive investment program and created a considerable number of new jobs," commented Kreuzburg. "By entering the business field of bioanalytics in the Lab Products & Services Division, we opened a new chapter and reached a substantially higher level of growth and profit margin. Given the high revenue base after two years of exceptionally strong expansion and despite several dampening effects, our bioprocess business increased yet again. For 2018, we will continue to pursue our targets of achieving significant profitable growth, investing extensively in innovations and capacities and of creating additional jobs."

All regions contributed to this strong performance. Asia|Pacific expanded the most, with sales up 22.5% to 344.6 million euros. EMEA2 grew by 6.8% to 604.5 million euros. In the Americas, the region in which Sartorius had recorded especially strong gains over the past years, sales revenue rose year over year by 3.5% to 455.5 million euros.

Order intake for the Sartorius Group was up 13.7% in 2017, increasing more strongly than sales. Demand in its bioprocess business picked up significantly, especially in the second half.

(All growth rates for the regions and order intake in constant currencies)

Underlying EBITDA rose by 8.5% in the reporting period, despite unfavorable currency effects, to 353.2 million, and the respective margin edged up slightly from 25.0% to 25.1%. Relevant net profit3 for the Group increased 8.6% from 132.6 million euros to 144.0 million euros. Consolidated earnings per ordinary share rose to 2.10 euros (prior-year period: 1.93 euros) and per preference share, 2.11 euros (prior-year period: 1.94 euros).

The Group's key financial indicators continued to remain at a strong level, even after the two acquisitions executed in 2017. At the end of the reporting period, the company's equity ratio was 35.1%, and the ratio of net debt to underlying EBITDA stood at 2.5 (Dec. 31, 2016: 42.0% and 1.5, respectively).

Capital expenditures rose in the reporting year from 152.1 million euros to 209.4 million euros due to considerable expansion of the Group's global infrastructure; the respective ratio of capital expenditures to sales revenue was 14.9% relative to 11.7% a year ago.

Sartorius employed 7,501 people worldwide at year-end 2017, thus 8.5% or 590 more people than a year earlier. Of this number, 214 employees joined the company due to acquisitions.

Business development of the divisions

The Bioprocess Solutions Division, which offers a wide array of innovative technologies for the manufacture of biopharmaceuticals, recorded full-year sales growth of 4.9% in constant currencies to 1,010.3 million euros in 2017, relative to a very high prior-year revenue base, with acquisitions accounting for around one percentage point of growth in this sales figure. The division's business development was dampened by several simultaneous and temporary effects, primarily impacting the Americas region. Thus, temporary bottlenecks in supply for its business with cell culture media, inventory destocking by a few large customers and an interruption in production at the plant in Puerto Rico following Hurricane Maria all had an impact. Order intake rose at a rate nearly twice as fast as sales revenue, reaching 9.7% in constant currencies after significant double-digit gains in the second half of the year.

The division's underlying EBITDA rose by 3.3% to 282.4 million euros. Despite unfavorable currency effects, the corresponding margin was 28.0%, at the prior-year level.

The Lab Products & Services Division, which offers products and technologies for laboratories primarily in the pharma sector and in life science research, recorded exceptionally dynamic growth due to its strong organic development and to a further acquisition in bioanalytics. The division's sales revenue rose by 22.0% to 394.2 million euros (reported: +21.2%), with around 14 percentage points of this expansion attributed to acquisitions. All regions and product areas contributed to this strong growth. In Lab Products & Services, order intake likewise increased at a faster pace than did sales, rising year over year by 25.8%.

Underlying EBITDA for the division also rose overproportionately with respect to sales, by 36.3% to 70.8 million euros. The division's margin climbed to 18.0% relative to 16.0% in the prior year.

Positive effects expected from U.S. tax reform

The U.S. tax reform approved in December 2017, which essentially lowers the U.S. corporate tax rate from 35% to 21%, resulted in the Sartorius Group in positive, non-cash extraordinary items of around 16 million euros during the reporting year, due to re-evaluation of deferred tax liabilities in the U.S. The corporate tax rate for the Group significantly decreased as a result of this effect from 29.0% a year earlier to 19.8% in the year under review.

A reduction in Sartorius' corporate tax rate by about 2 percentage points to around 27% is expected from 2018 onwards as a future effect. Since the changes in American tax legislation are very extensive, and further explanations and instructions for application by the U.S. tax authorities are still pending, this estimate is to be considered tentative.

Positive outlook for fiscal 2018

Sartorius again expects considerable profitable growth for the current year and therefore sees itself on track to reach its current mid-term targets set for 2020. Management thus projects that Group sales revenue for the full year will grow by about 9% to 12% and the company's underlying EBITDA margin will increase by about half a percentage point over the prior-year figure of 25.1%. The capex ratio will remain at the previous year's level of around 15%.

In view of the two divisions, management anticipates that sales for Bioprocess Solutions will grow by about 8% to 11% and that the division's underlying EBITDA margin will rise by around half a percentage point compared with the prior-year figure of 28.0%. For the Lab Products & Services Division, Sartorius projects that sales will grow approx. 12% to 15% and the division's underlying EBITDA margin will increase by about one percentage point (2017: 18.0%).

Because of the latest currency developments, reported figures in actual currencies might differ from constant currency guidance, and additional details will be provided as 2018 progresses.

1 Sartorius uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items) as the key profitability indicator
2 EMEA = Europe | Middle East | Africa
3 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Current image files

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG

Sartorius products used in the manufacture of medications

Sartorius bioanalytical systems used in pharmaceutical research

Upcoming financial dates

April 5, 2018 Annual Shareholders' Meeting

April 24, 2018 Publication of first-quarter figures (January to March 2018)

July 24, 2018 Publication of first-half figures (January to June 2018)

A Profile of Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.4 billion euros in 2017. More than 7,500 people work at the Group's approximately 50 manufacturing and sales sites, serving customers around the globe.

Key Performance Indicators for Fiscal 2017

    Sartorius Group       Bioprocess Solutions       Lab Products & Services    
in millions of € (unless otherwise specified)     2017      
2016
      Δ in % Reported       Δ in % cc1      
2017
     
2016
      Δ in % Reported       Δ in % cc1      
2017
     
2016
      Δ in % Reported       Δ in % cc1
Sales Revenue and Order Intake
Sales revenue     1,404.6       1,300.3       8.0       9.3       1,010.3       975.0       3.6       4.9       394.2       325.3       21.2       22.0
- EMEA2     604.5       569.1       6.2       6.8       413.8       406.9       1.7       2.5       190.7       162.2       17.6       17.7
- Americas2     455.5       445.4       2.3       3.5       357.1       374.6       -4.7       -3.3       98.4       70.8       39.0       39.5
- Asia | Pacific2     344.6       285.8       20.6       22.5       239.4       193.5       23.7       25.3       105.2       92.3       14.0       16.6
Order intake     1,501.4       1,334.7       12.5       13.7       1,091.3       1,006.5       8.4       9.7       410.1       328.1       25.0       25.8
Earnings
EBITDA3     353.2       325.4       8.5               282.4       273.5       3.3               70.8       51.9       36.3        
EBITDA margin3 in %     25.1       25.0                       28.0       28.0                       18.0       16.0                
Net profit for the period4     144.0       132.6       8.6                                                                        
Financial Data per Share
Earnings per ordinary share4 in €     2.10       1.93       8.6                                                                        
Earnings per preference share4 in €     2.11       1.94       8.6                                                                        

1 In constant currencies abbreviated as "cc"

2 Acc. to the customer's location
3 Underlying
4 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects.

Contact information

Sartorius AG
Petra Kirchhoff, +49 (0)551.308.1686
Vice President of Corporate Communications and IR
petra.kirchhoff@sartorius.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Villa Built as a ‘Private Museum’ in Lucca, Tuscany to Sell at Auction without Reserve via Concierge Auctions26.4.2019 16:12:00 EESTTiedote

Leading global marketplace Concierge Auctions is to sell Villa Angelina, an expansive villa and estate overlooking the picturesque walled city of Lucca, Italy. The property has been meticulously built with great expense, care and attention to detail in creating a private home suitable to display the owner’s collection of art masterpieces. As a result, it offers the highest level of contemporary design. Initially listed at €28million, Villa Angelina will sell without reserve to the highest bidder on 30 May. Bidding will open on 28 May. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190426005306/en/ (Photo: Business Wire) Villa Angelina offers 29,600 square feet (2,750 square metres) of accommodation within the main house, in addition to a further 12,700 square feet (1,180 square metres) of terraces. The light filled interiors include three large reception rooms, three master bedroom suites, a catering kitchen, office, cinema,

P&G Partners to Improve Environmental Impact and Smallholder Livelihood in Palm Oil Supply Chain26.4.2019 16:00:00 EESTTiedote

In celebration of Earth Week and to further its commitment to drive a more sustainable future, the Procter & Gamble Company (NYSE:PG) announced a new collaboration with Malaysia Institute for Supply Chain Innovation (MISI), International Plant Nutrition Institute (IPNI) and Yara International to help improve the livelihood of smallholders within the P&G palm supply chain in Malaysia. After a successful pilot ran between 2015 and 2018, the Company is expanding the program that partners with independent palm oil smallholders to increase their overall fruit yields through the training and implementation of best-in-class, and more sustainable agricultural practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190426005048/en/ To further our commitment to drive a more sustainable future, P&G has announced a new collaboration with MALAYSIA INSTITUTE FOR SUPPLY CHAIN INNOVATION (MISI), INTERNATIONAL PLANT NUTRITION INSTITUTE (IP

5 Modern Residences That Preserve and Showcase Artisanship26.4.2019 15:55:00 EESTTiedote

HONG KONG: K11 ARTUS This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190426005291/en/ Mr. Adrian Cheng, Founder of K11, Executive Vice-Chairman and General Manager of New World Development with Ms. Joyce Wang, internationally acclaimed interior designer for the K11 ARTUS penthouse. Following the launch of the hotly anticipated Rosewood Hong Kong in the art and design district Victoria Dockside, entrepreneur Adrian Cheng will unveil K11 ARTUS in the third quarter of this year, marking his fledging K11 group’s first luxury residence for rental, one with a social agenda to preserve fast-disappearing traditional craftsmanship. In the communal spaces is where the artisanal-living concept is truly apparent, filled as they are with pieces that have been produced in collaboration with K11 Craft & Guild Foundation, the latest of Cheng’s cultural initiatives, which seeks to protect craftsmanship techniques from the Ming and Qing dynast

Velodyne Expert Addresses How Lidar Boosts Business Value of Mobile Mapping Applications26.4.2019 15:00:00 EESTTiedote

Frank Bertini, UAV and Robotics Business Manager at Velodyne Lidar, Inc. (booth #1420), will deliver a featured presentation on the business cases for 3D lidar technology in mobile mapping applications at AUVSI XPONENTIAL 2019, taking place on April 29 to May 2, at McCormick Place in Chicago. Bertini will discuss revenue-generating strategies created by adding lidar to drones, backpacks, and all-terrain vehicles (ATV) to build autonomous solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190426005065/en/ Velodyne lidar sensors help systems developers by providing rich computer perception data that enables high-performing mapping systems in a lightweight, versatile solution. (Photo: Business Wire) Bertini’s session, “Emerging Autonomous Applications for 3D Lidar,” will provide a technical overview of industrial applications for lidar onboard unmanned systems. The presentation focuses on emerging use-cases which are cre

Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Marketing Authorization Application to the European Medicines Agency (EMA) for MDS and Beta-Thalassemia26.4.2019 14:30:00 EESTTiedote

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts, require red blood cell (RBC) transfusions and have received or are not eligible for erythropoiesis-stimulating agents, and for the treatment of adult patients with beta-thalassemia-associated anemia who require RBC transfusions. Luspatercept is an investigational erythroid maturation agent that regulates late-stage red blood cell maturation. The safety and efficacy results provided in the application are from the pivotal phase 3 studies MEDALIST and BELIEVE, evaluating the ability of luspatercept to effectively address anemia associated with MDS and beta-thalassemia, respectively. “As a first-in-class erythroid maturation ag

SES: First Quarter 2019 Results26.4.2019 09:00:00 EESTTiedote

SES S.A. announced its financial results for the three months ended 31 March 2019 with revenue and EBITDA in line with company expectations and SES on track to deliver on its 2019 financial outlook. Continued focus on execution has delivered major wins in the Networks business which is soon to be enhanced with the addition of four new O3b satellites, successfully launched at the beginning of April 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190425005955/en/ First Quarter 2019 Results Key financial highlights Reported revenue of EUR 480.6 million, (down 2.3% at constant FX(1)) in line with SES’ expectations Underlying revenue(2) of EUR 473.9 million; down 3.1%(1) (Video: -7.3%(1,2) and Networks +5.4%(1,2)) EBITDA of EUR 290.1 million representing a margin of 60.4% (Q1 2018: 63.7%); 62.1% excluding restructuring charge Net profit attributable to SES shareholders of EUR 72.2 million Free Cash Flow before financing acti

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme